ElevateBio BaseCamp Achieves ICMC™ Certification for Commercial Cell and Gene Therapy Manufacturing Capabilities
BaseCamp is the first genetic medicine manufacturing business to receive certification across viral gene delivery, non-viral gene delivery, and cell therapy products
WALTHAM, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced it has received comprehensive certification from the Initiative for Certification of Manufacturing Capabilities (ICMC™) program for its viral gene delivery, non-viral gene delivery, and cell therapy manufacturing capabilities at its flagship ElevateBio BaseCamp facility in Waltham, Massachusetts.
The ICMC certification, administered by Dark Horse Consulting (DHC), is designed to address the industry's most critical manufacturing challenges through assessment of capabilities to help reduce regulatory risk, accelerate development timelines, and increase probability of technical success. Through the certification process, DHC evaluates nine comprehensive systems, expanding upon the seven systems outlined in FDA's CBER Compliance Program Guidance Manual Chapter 45 for Biological Drug Products and incorporating EU Directive 2003/94/EC standards. Meeting the criteria of ICMC's comprehensive evaluation systems is a demonstration of ElevateBio's commitment to quality, compliance, and manufacturing excellence.
'This comprehensive ICMC certification represents the most rigorous third-party manufacturing evaluation available in our industry today," said Michael Paglia, Chief Technology Officer at ElevateBio BaseCamp. 'The nine-system framework proactively confirms our commercial manufacturing readiness across capabilities that satisfy and expand upon standard regulatory requirements. This certification across cell therapy, viral vector, and mRNA modalities underscores our unique capability to support a diverse range of advanced genetic medicine technologies and demonstrates our readiness to seamlessly scale manufacturing from clinical through commercial stages, enabling our partners to accelerate their path to market without manufacturing disruptions.'
ICMC Certification Criteria: Nine Systems for Commercial Manufacturing ReadinessThe ICMC certification program provides independent, third-party verification of manufacturing capabilities in the cell and gene therapy contract development and manufacturing organization (CDMO) market to enable therapeutic developers to make informed manufacturing partner selections. Through this certification, the BaseCamp Waltham process development and cGMP manufacturing facility has demonstrated proficiency across nine critical systems:
Service Business System: Ensures reliable partnership and project management and seamless knowledge/technology transfer into a GMP environment, including a review of the Person in Plant framework and business continuity response plans, critical for therapeutic developers navigating complex manufacturing partnerships
Quality System: Provides rigorous quality system framework that reduces approval risks, ensures compliance, and accelerates time-to-market for advanced therapies
Digital System: Delivers data integrity and cybersecurity, essential for protecting intellectual property and meeting stringent regulatory data handling requirements
Facilities and Equipment System: Ensures controlled manufacturing environments specifically designed for advanced therapies. Demonstrates cross contamination control
Materials System: Enables reliable supply chain management of inventory, from procurement through testing, release, and storage: critical for therapies dependent on precisely-specified starting materials
Production System: Ensures consistent, reproducible manufacturing processes essential for therapeutic efficacy and safety across clinical and commercial scales. Verifies that products can be produced aseptically.
Packaging and Labeling System: Maintains product identity and chain of custody throughout the manufacturing process.
Laboratory Control System: Provides reliable testing and verification methods critical for quality release decisions and regulatory submissions, from initial transfer through qualification and validation
Commercial Readiness: Establishes manufacturing scale-up capabilities and process validation protocols required for successful transition from clinical to commercial production
The independent certification process employed regulatory-grade methodologies over several weeks, including multiple days of on-site verification and interviews, covering hundreds of documents. Importantly, these global quality systems in place set a strong foundation for commercial readiness at ElevateBio's BaseCamp Pittsburgh facility, which is under construction at Hazelwood Green and is expected to be operational in 2027.
Certification from Leading Cell and Gene Therapy CDMO Consulting GroupDark Horse Consulting brings proven industry expertise to the ICMC certification process, having performed more than 60 cell and gene therapy CDMO selection projects and over 50 regulatory-style audits in the past four years. DHC's evaluation team includes former regulatory officials who apply the same rigorous standards used in official regulatory inspections, ensuring ICMC certification provides a meaningful audit of manufacturing capabilities.
"ElevateBio BaseCamp's ICMC certification demonstrates exactly the kind of comprehensive manufacturing capabilities that therapeutic developers need in order to reduce regulatory risk and accelerate their timelines," said Anthony Davies, Founder and CEO at Dark Horse Consulting. "Partners working with ElevateBio BaseCamp can expect standardized, reproducible manufacturing practices that have been rigorously evaluated against industry requirements, to ensure quality, compliance, and adherence to regulatory standards. This certification provides therapeutic developers with increased probability of technical success through verified manufacturing excellence."
About ElevateBioElevateBio is a technology-driven company built to power transformative genetic medicines today and for many decades to come. The Company applies its enabling technologies, manufacturing capabilities, and industry-leading expertise through partnerships to accelerate development across a breadth of therapeutic approaches and modalities. The ElevateBio ecosystem combines Life Edit, its gene editing and R&D technology business, with BaseCamp®, its end-to-end genetic medicine cGMP manufacturing and process development business, to accelerate the discovery and development of advanced therapeutics.
ElevateBio aims to be the dominant engine inside the world's greatest scientific advancements harnessing human cells and genes to alter disease. For more, visit www.elevate.bio or follow ElevateBio on LinkedIn or X.
Investor contact:Catherine Huchu@elevate.bio
Media contact:DJ Websterdwebster@elevate.bioSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Sprinklr, Procore, Alarm.com, and Pegasystems Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after the SaaS sector continued to rally as favorable inflation data bolstered hopes for a Federal Reserve interest rate cut. This optimism was largely driven by a benign July Consumer Price Index (CPI) report, which solidified investor expectations for a Federal Reserve interest rate cut. Following the release of the inflation data, which showed a year-over-year increase of 2.7%, the probability of a rate cut in September surged to over 96%. Lower interest rates are typically beneficial for growth-oriented technology stocks, as they can reduce borrowing costs and increase the present value of future earnings. Adding to the positive sentiment was a 90-day delay in the imposition of higher tariffs on Chinese goods, which reduced trade-related uncertainty for the technology sector. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Customer Experience Software company Sprinklr (NYSE:CXM) jumped 3.4%. Is now the time to buy Sprinklr? Access our full analysis report here, it's free. Design Software company Procore (NYSE:PCOR) jumped 3.4%. Is now the time to buy Procore? Access our full analysis report here, it's free. Vertical Software company (NASDAQ:ALRM) jumped 4.4%. Is now the time to buy Access our full analysis report here, it's free. Automation Software company Pegasystems (NASDAQ:PEGA) jumped 3.2%. Is now the time to buy Pegasystems? Access our full analysis report here, it's free. Zooming In On (ALRM) shares are not very volatile and have only had 5 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. is down 3.1% since the beginning of the year, and at $57.95 per share, it is trading 15.8% below its 52-week high of $68.81 from December 2024. Investors who bought $1,000 worth of shares 5 years ago would now be looking at an investment worth $1,012. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
Sam Altman To Back Merge Labs, Neuralink Rival
Microsoft (NASDAQ:MSFT)-backed OpenAI co-founder Sam Altman is gearing up to back Merge Labs, a new brain-computer interface startup that could go head-to-head with Elon Musk's Neuralink, the Financial Times reported. Merge Labs is raising about $250 million at an 850Million valuation, with a big chunk expected from OpenAI's ventures arm. Altman is not putting in personal money and will not run day-to-day. He is launching the project with Alex Blania, who leads World, and the plan is ambitious: build advanced neural implants that link human cognition with AI. Warning! GuruFocus has detected 7 Warning Sign with MSFT. The move adds another chapter to the Altman-Musk rivalry since Musk left OpenAI in 2018 and signals rising investor appetite for invasive neurotech. It also brings real-world hurdles. This space needs careful clinical testing, ethical guardrails and an FDA pathway before anything reaches broad use. This article first appeared on GuruFocus.
Yahoo
4 minutes ago
- Yahoo
Back to Basics for Activists: ICR Global Head of Governance Gabriel Hasson, Live at Nasdaq
CorpGov hosted a fireside chat on August 12 at Nasdaq MarketSite with Gabriel Hasson, Global Head of Governance and Shareholder Advisory, Managing Director at ICR. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed why activists are going back to basics and what it means in practice, what companies get consistently wrong about IPO prep, and the experience he brings to his new role at ICR. Watch the interview below, or click : About ICR Founded in 1998 by three former Wall Street analysts and lifelong collaborators, ICR was built to develop and deliver impactful strategic communications and advisory solutions for companies at every stage of growth. In the decades since, we've earned recognition globally for our expertise in public relations, investor relations, corporate and capital markets advisory solutions and our unparalleled ability to provide coordinated, sector-focused solutions to leaders in every industry for every complex scenario. More at About Gabriel Hasson Gabriel Hasson is the Global Head of Governance & Shareholder Advisory at ICR, where he helps companies navigate the intersection of corporate governance, shareholder engagement, and capital markets strategy. He advises boards and executives on assessing, improving, and communicating governance practices tied to material governance, environmental, and social risks and opportunities. His team also supports and executes shareholder engagement, helping clients build investor trust and respond to activism, M&A, and other high-stakes situations. Gabe has advised public companies and institutional investors on high-stakes shareholder matters including contested director elections, activism defense, executive compensation and equity plan scrutiny, board and leadership transitions, and proxy season preparation. His experience spans sectors such as healthcare, technology, energy, consumer goods, and financial services, with mandates covering Fortune 500 companies in the U.S. and Canada and leading issuers across Latin America and other emerging markets, particularly around governance, environmental, and social risks tied to long-term value creation. Prior to joining ICR, Gabe was an Investment Stewardship Director at BlackRock, overseeing a portfolio of over $400 billion across the U.S., Canada, and Latin America. Earlier, he was an M&A attorney advising global corporations on complex cross-border transactions and held senior roles at Institutional Shareholder Services (ISS) and Deloitte, where he counseled federal governments and Fortune 500 clients on shareholder engagement, corporate governance, sustainability, and stewardship priorities. Gabe holds a law degree from Universidad Panamericana, a certificate in U.S. Law from The George Washington Law School, a master's in international public policy from Johns Hopkins SAIS, and a certificate in corporate finance from Cornell University. Gabe currently serves on the Public Policy Committee of the International Corporate Governance Network (ICGN) and is an advisory board member of BH Compliance. READ MORE LA CorpGov Forum Sept 4: Featuring Sports, Entertainment & International Business Register for our weekly newsletter Contact:Click to follow us on LinkedIn The post Back to Basics for Activists: ICR Global Head of Governance Gabriel Hasson, Live at Nasdaq appeared first on CorpGov.
